Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial

GlobeNewswire November 7, 2018

Hemostemix Announces OTCQB Listing and DTC Eligibility

GlobeNewswire October 30, 2018

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial

GlobeNewswire October 9, 2018

Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders

GlobeNewswire September 27, 2018

Hemostemix Announces Addition to Its Clinical Trial Management Team

GlobeNewswire September 24, 2018

Hemostemix Announces Two New Strategic Trial Sites in Texas

GlobeNewswire August 16, 2018

Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial

GlobeNewswire July 18, 2018

Hemostemix Formalizes World-Class Scientific Advisory Board

GlobeNewswire July 5, 2018

Hemostemix Announces Major Milestone Achieved With First 3 U.S. Trial Sites for Phase II Clinical Trial Open for Patient Enrollment

GlobeNewswire May 30, 2018

Hemostemix Announces New EU Patent Grant

GlobeNewswire May 23, 2018

Hemostemix Announces First Patient Treated in Phase II Clinical Trial

GlobeNewswire May 3, 2018

Hemostemix Announces US FDA Clinical Trial Approval

GlobeNewswire April 19, 2018

Hemostemix Signs License Agreement with Aspire Health Science

GlobeNewswire February 26, 2018

Hemostemix Signs License Agreement with Aspire Health Science

GlobeNewswire February 23, 2018

Hemostemix Signs Manufacturing Agreement with Aspire Health Science

GlobeNewswire February 22, 2018

Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials

GlobeNewswire December 20, 2017

Hemostemix Drives Forward with Talented New Management into New Headquarters

GlobeNewswire November 30, 2017

Hemostemix Announces Agreement with CRO Service Provider Topstone Research

GlobeNewswire September 26, 2017

Acquisition and Disposition of Securities of Hemostemix Inc.

Marketwired September 19, 2017

Hemostemix Completes Conversion of Subscription Receipts and Secured Credit Financing

GlobeNewswire September 15, 2017